Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/57542
Title: Current and Future Neuropharmacological Options for the Treatment of Essential Tremor.
Authors: 
Keywords: 
Mesh: 
Issue Date: 2020
Citation: Curr Neuropharmacol.2020;(18)6:518-537
Abstract: Essential Tremor (ET) is likely the most frequent movement disorder. In this review, we have summarized the current pharmacological options for the treatment of this disorder and discussed several future options derived from drugs tested in experimental models of ET or from neuropathological data. A literature search was performed on the pharmacology of essential tremors using PubMed Database from 1966 to July 31, 2019. To date, the beta-blocker propranolol and the antiepileptic drug primidone are the drugs that have shown higher efficacy in the treatment of ET. Other drugs tested in ET patients have shown different degrees of efficacy or have not been useful. Injections of botulinum toxin A could be useful in the treatment of some patients with ET refractory to pharmacotherapy. According to recent neurochemical data, drugs acting on the extrasynaptic GABAA receptors, the glutamatergic system or LINGO-1 could be interesting therapeutic options in the future.
PMID: 31976837
URI: https://hdl.handle.net/20.500.12530/57542
Rights: openAccess
Appears in Collections:Hospitales > H. U. Sureste > Artículos

Files in This Item:
File SizeFormat 
PMC7457404.pdf724.24 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.